Brought to you by 
Single investor buys 16mm common shares of Cell Therapeutics
21 May 2009
Executive Summary
On the heels of a $20mm preferred stock placement completed in April, cancer company Cell Therapeutics netted $19mm through the sale this month of 16mm common shares at $1.25 each (an 89% premium) to Iroquois Master Fund. The sole investor also received five-year warrants to purchase up to 4.8mm more shares at an exercise price of $1.40. Rodman & Renshaw was the placement agent.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Single investor buys 16mm common shares of Cell Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice